CL2011002690A1 - Uso de un compuestos especificos derivados de pirimidin-2,4-diamina, inhibidores de pkc-teta para tratar un trastorno inmunologico o la aterosclerosis. - Google Patents

Uso de un compuestos especificos derivados de pirimidin-2,4-diamina, inhibidores de pkc-teta para tratar un trastorno inmunologico o la aterosclerosis.

Info

Publication number
CL2011002690A1
CL2011002690A1 CL2011002690A CL2011002690A CL2011002690A1 CL 2011002690 A1 CL2011002690 A1 CL 2011002690A1 CL 2011002690 A CL2011002690 A CL 2011002690A CL 2011002690 A CL2011002690 A CL 2011002690A CL 2011002690 A1 CL2011002690 A1 CL 2011002690A1
Authority
CL
Chile
Prior art keywords
teta
pkc
atherosclerosis
pyrimidin
diamine
Prior art date
Application number
CL2011002690A
Other languages
English (en)
Inventor
Maryanne Brow
Michael Dustin
Zhorov Alexandra Zanin
Original Assignee
Boehringer Ingelheim Int
Univ New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42332785&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011002690(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int, Univ New York filed Critical Boehringer Ingelheim Int
Publication of CL2011002690A1 publication Critical patent/CL2011002690A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Un método para tratar un trastorno inmunológico o la aterosclerosis que comprende tratar la sangre del paciente con un inhibidor de pkc-teta ex vivo y luego readministrar la sangre tratada.
CL2011002690A 2009-04-28 2011-10-27 Uso de un compuestos especificos derivados de pirimidin-2,4-diamina, inhibidores de pkc-teta para tratar un trastorno inmunologico o la aterosclerosis. CL2011002690A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17323709P 2009-04-28 2009-04-28

Publications (1)

Publication Number Publication Date
CL2011002690A1 true CL2011002690A1 (es) 2012-04-27

Family

ID=42332785

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011002690A CL2011002690A1 (es) 2009-04-28 2011-10-27 Uso de un compuestos especificos derivados de pirimidin-2,4-diamina, inhibidores de pkc-teta para tratar un trastorno inmunologico o la aterosclerosis.

Country Status (14)

Country Link
US (1) US20120196919A1 (es)
EP (1) EP2445503A1 (es)
JP (1) JP2012525403A (es)
KR (1) KR20120005460A (es)
CN (1) CN102421435A (es)
AU (1) AU2010241701A1 (es)
BR (1) BRPI1014775A2 (es)
CA (1) CA2760305A1 (es)
CL (1) CL2011002690A1 (es)
EA (1) EA201101568A1 (es)
IL (1) IL215939A0 (es)
MX (1) MX2011011290A (es)
NZ (1) NZ595331A (es)
WO (1) WO2010126967A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102908690A (zh) 2007-08-31 2013-02-06 密执安州立大学董事会 选择性细胞隔离装置及其相关方法
JP5937003B2 (ja) * 2009-05-18 2016-06-22 セラコス・インコーポレイテッドＴｈｅｒａｋｏｓ， Ｉｎｃ． 免疫介在性疾患における臨床応用のための、抑制機能の高められた制御性ｔ細胞のエクスビボ増加方法
WO2012006060A1 (en) 2010-06-28 2012-01-12 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
WO2012006055A2 (en) 2010-06-28 2012-01-12 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
EP2606041A2 (en) 2010-08-17 2013-06-26 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flaviviridae viral infections
WO2012051595A1 (en) 2010-10-15 2012-04-19 Cytopherx, Inc. Cytopheresic cartridge and use thereof
WO2012174412A2 (en) * 2011-06-16 2012-12-20 La Jolla Institute For Allergy And Immunology Compositions targeting pkc-theta and uses and methods of treating pkc-theta pathologies, adverse immune responses and diseases
TW201317223A (zh) 2011-07-26 2013-05-01 Vertex Pharma 噻吩化合物
WO2013016499A1 (en) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Methods for preparation of thiophene compounds
EP2802367A4 (en) 2012-01-09 2015-12-16 H David Humes CARTRIDGE AND METHOD FOR INCREASING MYOCARDIAL FUNCTION
WO2013142157A1 (en) 2012-03-22 2013-09-26 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
PT2953634T (pt) 2013-02-07 2021-09-02 Massachusetts Gen Hospital Métodos de expansão ou depleção das células t reguladoras
WO2014134251A1 (en) 2013-02-28 2014-09-04 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
PT3221308T (pt) 2014-11-21 2018-12-17 F2G Ltd Agentes antifúngicos
WO2016187068A1 (en) 2015-05-15 2016-11-24 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
WO2017041002A1 (en) * 2015-09-04 2017-03-09 Blazar Bruce R Methods and compositions for increasing the suppressive function of regulatory t-cells (tregs)
EP3355914B1 (en) 2015-09-29 2024-03-06 The General Hospital Corporation A composition comprising bcg for reducing cholesterol.
KR102410778B1 (ko) 2016-05-13 2022-06-21 더 제너럴 하스피탈 코포레이션 길항성 항-종양 괴사 인자 수용체 슈퍼패밀리 항체
GB201609222D0 (en) 2016-05-25 2016-07-06 F2G Ltd Pharmaceutical formulation
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
US11819503B2 (en) 2019-04-23 2023-11-21 F2G Ltd Method of treating coccidioides infection

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003032997A1 (de) * 2001-10-17 2003-04-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung
WO2004043386A2 (en) * 2002-11-08 2004-05-27 Tolerrx, Inc. Molecules preferentially associated with effector t cells and methods of their use
ATE440087T1 (de) * 2003-01-30 2009-09-15 Boehringer Ingelheim Pharma 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen
US7601714B2 (en) * 2004-07-08 2009-10-13 Boehringer Ingelheim Pharmaceuticals, Inc. Pyrimidine derivatives useful as inhibitors of PKC-theta

Also Published As

Publication number Publication date
CA2760305A1 (en) 2010-11-04
KR20120005460A (ko) 2012-01-16
NZ595331A (en) 2013-08-30
US20120196919A1 (en) 2012-08-02
CN102421435A (zh) 2012-04-18
EA201101568A1 (ru) 2012-05-30
BRPI1014775A2 (pt) 2016-04-19
AU2010241701A1 (en) 2011-10-13
MX2011011290A (es) 2012-02-13
IL215939A0 (en) 2012-01-31
JP2012525403A (ja) 2012-10-22
WO2010126967A1 (en) 2010-11-04
EP2445503A1 (en) 2012-05-02

Similar Documents

Publication Publication Date Title
CL2011002690A1 (es) Uso de un compuestos especificos derivados de pirimidin-2,4-diamina, inhibidores de pkc-teta para tratar un trastorno inmunologico o la aterosclerosis.
EA201790142A1 (ru) Лечение лейкоза ингибиторами гистондеацетилазы
EA201790195A1 (ru) Способы лечения рака с применением ингибиторов tigit и противораковых агентов
MX2020004023A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
AR092899A1 (es) Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion
EA201792191A1 (ru) Комбинированная терапия fgfr/pd-1 для лечения злокачественной опухоли
BR112015009948A2 (pt) antagonistas de ativina-actriia e usos para tratamento ósseos e outros disturbios
PH12015501868A1 (en) Inhibitors of histone demethylases
EP4306542A3 (en) Treatment of lag-3 positive tumors
CR20120173A (es) Combinaciones de un inhibidor de pi3k y un inhibidor de mek
UY35313A (es) Antiadhesion de leucocitos para mitigar los potenciales eventos adversos causados por los dominios de unión específicos de cd3
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
EA201390060A1 (ru) Аннелированные пиримидины и триазины и их применение для лечения и/или профилактики сердечно-сосудистых заболеваний
EP2575884A4 (en) APPLICATIONS AND COMPOSITIONS FOR THE TREATMENT OF ACNE INVERSA
EA201301354A1 (ru) Ингибиторы sglt-2, предназначенные для лечения метаболических нарушений у пациентов, леченных нейролептиками
CO7160059A2 (es) Formulación líquida
EA201490194A1 (ru) Комбинированная терапия, включающая ингибитор cdk4/6 и ингибитор pi3k для применения в лечении рака
BR112014009993A2 (pt) método para o tratamento de tumores do estroma gastrointestinal
MX2017013496A (es) Tratamiento de enfermedad cronica de injerto contra hospedero con inhibidores de tirosina cinasa de bazo (syk).
EA201690745A1 (ru) Способы лечения и предотвращения болезни "трансплантат против хозяина"
CL2008002089A1 (es) Compuesto para la regeneracion de tejidos que comprende al menos una sustancia derivada de sangre y acido hialuronico y/o al menos un compuesto derivado de acido hialuronico; metodo para la prepararcion de dicho compuesto.
BR112014028041A2 (pt) tratamento de obesidade hipotalâmica com inibidores de metap2
BR112015027477A2 (pt) método para tratamento de um transtorno de deglutição
WO2010123527A3 (en) Use of epidermal growth factor inhibitors in the treatment of viral infection
EA201691020A1 (ru) Способы лечения и предотвращения вызываемой аллогенными антителами хронической болезни "трансплантат против хозяина"